A recent study has found that patients who receive higher doses of buprenorphine, a medication commonly used to alleviate opioid withdrawal and cravings, are less likely to be hospitalized and less likely to discontinue treatment. This discovery contradicts current federal guidelines, which recommend a target dose of 16 mg. With fentanyl becoming more prevalent in the U.S. drug supply, addiction treatment providers have reported that patients often require significantly higher doses of buprenorphine to reduce or stop their illicit opioid use.
The study, published in JAMA Network Open, revealed that patients receiving 24 mg or more of buprenorphine were less likely to visit the emergency room or require other inpatient care compared to those receiving lower doses. Initially, the researchers set out to investigate whether higher doses of buprenorphine were associated with harmful outcomes but instead found a benefit. Patients receiving higher doses were not only less likely to end up in the emergency department but also took longer to require emergency care.
Buprenorphine, also known as Suboxone, and methadone are considered the gold standard for treating opioid use disorder. However, as the drug supply has become more potent, transitioning patients from fentanyl to addiction medications like buprenorphine has become more challenging. Buprenorphine can cause precipitated withdrawal if not administered correctly, leading to symptoms such as pain, anxiety, sweating, and gastrointestinal distress. Despite being an opioid itself, buprenorphine binds to the brain’s opioid receptors differently than pain medications or fentanyl, effectively outcompeting other opioid molecules for receptor space without providing the same euphoric or analgesic effects.
To address these challenges, addiction doctors have explored various methods for initiating patients on buprenorphine, including large loading doses, microdosing, and combining the medication with small amounts of ketamine. The new study adds to existing evidence supporting the safety and efficacy of higher buprenorphine doses in helping patients remain in treatment. Another recent study showed that higher initial buprenorphine doses are linked to lower mortality rates, prompting the American Society of Addiction Medicine to advocate for giving clinicians more flexibility in determining medically appropriate doses.
Despite the positive outcomes associated with higher buprenorphine doses, access to these doses remains limited. Stigma surrounding addiction medications, including buprenorphine, often deters doctors from prescribing them. Additionally, insurance requirements, prior authorization processes, and FDA recommendations can prevent doctors from prescribing doses exceeding 16 or 24 mg, leading to treatment failures for some patients.
Federal agencies are actively discussing the issue, with a recent “listening session” hosted by the Substance Abuse and Mental Health Services Administration, FDA, and National Institute on Drug Abuse to evaluate current buprenorphine dosing guidelines. The hope is that the growing body of evidence and evolving attitudes towards buprenorphine prescribing will prompt the FDA to reconsider its dosing recommendations, which could influence insurance coverage and state regulations.
In conclusion, the study’s findings underscore the importance of considering higher buprenorphine doses for patients with opioid use disorder. By recognizing the potential benefits of higher doses and addressing barriers to access, healthcare providers can better support individuals seeking treatment for opioid addiction.
